Duchenne Muscular Dystrophy Market (DMD) Insight (2022–2031)
The global Duchenne muscular dystrophy market size was valued at $1,301.44 Million in 2021, and is estimated to reach $2,073.91 Million by 2031, growing at a CAGR of 4.7% from 2022 to 2031.
A genetic condition known as Duchenne muscular dystrophy (DMD) is characterized by progressive muscle weakness and degradation as a result of changes to a protein called dystrophin that keeps muscle cells intact. DMD typically affects men, though it can occasionally affect women as well. Progressive weakening and loss (atrophy) of both skeletal and cardiac muscle are signs of DMD. Early warning indicators include difficulty in learning to talk and a delay in sitting, standing, or walking. Early childhood is typically when muscle weakness becomes apparent.
Cardiomyopathy or respiratory muscle weakness are the most common causes of death in people in the twenties, and cardiac and orthopedic issues are common. To avoid orthopedic problems, current treatment focuses on glucocorticoid therapy and physical therapy. Most patients start needing a wheelchair around the age of 10 to 12 and require assisted breathing around the age of 20. Most DMD patients with the best care pass away between the ages of 20 and 40 from cardiac and/or respiratory failure.
Duchenne muscular dystrophy is brought on by dystrophin gene mutations (DMD). The dystrophin gene contains 79 exons, and deletion mutations often affect multiple exons—which make up the majority of DMD alterations. Exon skipping is a DMD therapy that was created in response to the discovery of "reverent" fibers in the dystrophic muscle that can vary depending on the precise mutation. Exon skipping therapy is being introduced by a number of major market participants to treat Duchenne muscular dystrophy drives the market growth.
In addition, the rise in the incidence of the Duchenne muscular dystrophy (DMD) propels the market growth fuels the market growth. Furthermore, drug development has been quite active in recent years, with many research groups focused on the creation of novel medications for the treatment of DMD propels the Duchenne muscular dystrophy market growth.
However, the inflated cost of treatments for Duchenne muscular dystrophy is anticipated to limit the adoption of treatments during the forecast period. Conversely, rising need for better healthcare services, the healthcare sector is expanding significantly in both established and emerging economies. During the forecast period, the market for treatments is anticipated to benefit from rising government spending on the pharmaceutical and biotechnology sectors in developing countries, the development of healthcare infrastructure, and the rising demand for innovative treatments for Duchenne muscular dystrophy
COVID-19 Impact on Duchenne Muscular Dystrophy Market:
The COVID-19 pandemic is predicted to have a negative impact on the growth of the global Duchenne muscular dystrophy market. However, throughout the pandemic, despite the recommendations to maintain social distance, many individuals treated their illnesses via self-medication or other unconventional methods owing to their concern of contracting COVID during the lockdown.
Duchenne Muscular Dystrophy Segmentation
The Duchenne muscular dystrophy market is segmented on the basis of therapeutic area, distribution channel, and region. On the basis of therapeutic area, the market is categorized into molecular based therapies and steroid therapy. By distribution channel, it is classified into hospital pharmacies, drug store & retail pharmacies, and online Pharmacies. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa (LAMEA).
By Therapeutic Area
Molecular-based Therapies holds a dominant position in 2021 and would continue to maintain the lead over the forecast period.
Segment Review
By therapeutic area, the market is segmented into molecular based therapies and steroid therapy. The molecular based therapies segment generated maximum revenue in 2021 and is expected to witness highest CAGR during the forecast period, owing to strong product pipeline and rise in product launch.
Depending on distribution channel, the market is divided into hospital pharmacies, drug store & retail pharmacies and online pharmacies. The hospital pharmacies segment dominated the market in 2021, owing to hospitals are primary source of treatment for patients. The drug store & retail pharmacies segment is expected to witness highest CAGR during the forecast period owing to it offers wide range of corticosteroids.
By Application
Drug Store & Retail Pharmacies segment is projected as one of the most lucrative segment.
North America accounted for a majority of the global Duchenne muscular dystrophy drug market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to technological advancements in Duchenne muscular dystrophy, presence of key and robust hospital infrastructure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing rise in case of Duchenne muscular dystrophy, development of healthcare infrastructure and increase in investments projects in the region.
The major players profiled in the report are F Hoffmann-La Roche AG, FibroGen, Inc, GlaxoSmithKline plc, Italfarmaco S.p.A., Nippon Shinyaku Co., Ltd, Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals Inc, Sarepta therapeutics and Wave life sciences ltd.
By Region
Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 5.9% during the forecast period.
Key Benefits For Stakeholders
- The report provides an in-depth analysis of the Duchenne muscular dystrophy market size along with the current trends and future estimations to elucidate imminent investment pockets.
- It offers market analysis from 2022 to 2031, which is expected to enable stakeholders to capitalize on prevailing opportunities in the Duchenne muscular dystrophy market.
- A comprehensive analysis on region assists to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
- The profiles and growth strategies of key players are thoroughly analyzed to understand competitive outlook of the global Duchenne muscular dystrophy treatment market growth.
Duchenne Muscular Dystrophy Market Report Highlights
| Aspects | Details |
 By Therapeutic Class |
|
 By Region |
|
 By Key Market Players |
|
Analyst Review
This section provides opinions of top level CXOs in the global Duchenne muscular dystrophy market. According to the insights of CXOs, leading companies in the market and development of advanced & reliable Duchenne muscular dystrophy therapeutics have led to extensive number of applications of this drug. Increase in prevalence of the disease and better healthcare services are expected to propel the Duchenne muscular dystrophy market.
Market growing at a steady rate in developed nations, Asia-Pacific and LAMEA are expected to offer high growth opportunities to key players in this market. According to the perspectives of CXOs of leading companies in the market, significant advancements in the Duchenne muscular dystrophy with increase in clinically backed research, growing investments, funds & grants, increasing incidence of disease, entry of new players, and strong product pipeline are projected to fuel the market growth.
The total market value of duchenne muscular dystrophy market is $1,301.44 million in 2021
The forecast period for duchenne muscular dystrophy market is 2022 to 2031
The market value of duchenne muscular dystrophy market in 2031 is $2,073.91 million.
The base year is 2021 in duchenne muscular dystrophy market
Top companies such as F Hoffmann-La Roche AG, FibroGen, Inc, GalaxoSmithKline plc, Italfarmaco S.p.A., Nippon Shinyaku Co., Ltd, Pfizer Inc., PTC Therapeutics, Santhera Pharmaceuticals Inc, Sarepta therapeutics, and Wave life sciences Ltd., held a high market position in 2021.
Molecular Therapies segment dominated the global market in 2021, and expected to continue this trend throughout the forecast period due to R & D for new exon skipping technologies for the treatment of duchenne muscular dystrophy.
Increase in prevalence of diseases, launch of molecular therapies and various technological advancements in duchenne muscular dystrophy is anticipated to drive the market in the forecast period.
North America is projected to account for a major share of the global duchenne muscular dystrophy market during the forecast period. U.S. dominated the North America duchenne muscular dystrophy market owing to approval and availability of drugs in the region.
Loading Table Of Content...
